Trials / Unknown
UnknownNCT02416427
Targeting the Hippo Transducer TAZ in Breast Cancer With Statins
A Phase II, Randomized, Non-comparative, Pre-surgical Study of Atorvastatin or Observation in Ki-67 Positive, TAZ-expressing Early Breast Cancer Patients (TRINACRIA Trial)
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 78 (estimated)
- Sponsor
- Regina Elena Cancer Institute · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This pre-surgical, window-of-opportunity study is designed to investigate whether atorvastatin reduces the proliferation marker Ki-67 via modulation of the Hippo transducer TAZ.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Atorvastatin | Atorvastatin will be administered at 80 mg/day for 3 weeks in the time window between diagnostic biopsy and curative surgery |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2016-12-01
- Completion
- 2016-12-01
- First posted
- 2015-04-15
- Last updated
- 2015-04-15
Source: ClinicalTrials.gov record NCT02416427. Inclusion in this directory is not an endorsement.